1	Anti-CD20 antibodies in relapsing multiple sclerosis: Protocol for a systematic
2	review and network meta-analysis
3	
4	Short title: Anti-CD20 in multiple sclerosis: a network meta-analysis
5	
6	Authors and affiliations
7	Cristian Eduardo Navarro ¹² *, Simón Cárdenas-Robledo ³⁴ , Jaiver Macea ⁵ , Natalia A
8	Ortíz-Cano ⁶ , Ivan D Florez ⁷⁸⁹
9	
10	¹ School of Medicine, Universidad de Antioquia. Medellín, Colombia
11	² Grupo de Investigación E.S.E Hospital Emiro Quintero Cañizares. Ocaña, Colombia
12	³ Centro de Esclerosis Múltiple, Hospital Universitario Nacional (CEMHUN). Bogotá,
13	Colombia
14	⁴ Departamento de Medicina Interna, Universidad Nacional de Colombia. Bogotá,
15	Colombia
16	⁵ Research Group Experimental Neurology, Department of Neurosciences, KU Leuven.
17	Leuven, Belgium
18	⁶ Pharmacy Department, Hospital Pablo Tobón. Medellín, Colombia
19	⁷ Department of Pediatrics, University of Antioquia. Medellín, Colombia
20	⁸ School of Rehabilitation Science, McMaster University. Hamilton, Canada
21	⁹ Pediatric Intensive Care Unit, Clínica Las Americas-AUNA. Medellín, Colombia
22	
23	* Corresponding autor:
24	E-mail: cristian.navarro@udea.edu.co

25 Abstract

26 **Background:** Multiple sclerosis is a chronic disease of the central nervous system 27 characterized by autoimmune demyelination. Various immunomodulatory medications 28 are available for its treatment, among which anti-CD20 monoclonal antibodies have 29 demonstrated superior efficacy compared to other disease-modifying therapies. 30 However, there is a lack of direct comparison between the four available anti-CD20 31 monoclonal antibodies. Therefore, this study aims to systematically assess the relative 32 efficacy and safety of anti-CD20 monoclonal antibodies for treating relapsing multiple 33 sclerosis. 34 Materials and Methods: We will conduct a systematic review of phase IIb and phase 35 III clinical trials of anti-CD20 monoclonal antibodies for the treatment of relapsing 36 multiple sclerosis, following the Preferred Reporting Items for Systematic Reviews and 37 Meta-Analysis guidelines. A comprehensive review of the Cochrane Central Register of 38 Controlled Trials; MEDLINE; Embase; ClinicalTrials; International Clinical Trials 39 Registry Platform; OpenGray; and MedRxiv will be performed. Two independent 40 reviewers will select titles, abstracts, and eligible full texts to execute the data 41 extraction. The risk of bias will be assessed with the Cochrane RoB 2 tool. Data on pre-42 specified outcomes will be analyzed for the selected articles using a random-effects 43 network meta-analysis with a frequentist framework. Summary statistics, along with 44 95% confidence intervals will be presented, and the effectiveness and safety of each 45 intervention will be ranked using the surface under the cumulative ranking curve. A 46 missing data and a sensitivity analysis will be conducted. We will use the GRADE 47 approach to assess the certainty of the direct, indirect, and network estimate for all

48 outcomes.

- 49 **Results and Conclusion:** The results will provide evidence of the relative efficacy and
- 50 safety of anti-CD20 monoclonal antibodies for the treatment of relapsing multiple
- 51 sclerosis.
- 52 Systematic review registration: PROSPERO registration number CRD42023437996

53 Introduction

54 Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 55 (CNS) that affects millions of people worldwide [1,2]. MS is characterized by the loss 56 of myelin, which leads to impaired nerve function and disability. Demyelination was 57 traditionally considered to be caused by autoreactive T lymphocytes [3], but the role of 58 B lymphocytes in the MS pathogenesis has been increasingly recognized during the last 59 two decades [4]. As a result, B cell depleting anti-CD20 monoclonal antibodies have 60 emerged as promising disease-modifying therapies (DMTs) for MS [5–8]. Early phase 1 61 and phase 2 trials showed reduction in magnetic resonance imaging (MRI) activity (in 62 the form of new/enlarging FLAIR/T2 lesions and gadolinium-enhancing [Gd+] lesions) 63 and a discrete reduction in the long-term clinical outcome in people with inflammatory 64 activity in MRI after treatment with rituximab [9,10]. 65

66 Three new anti-CD20 monoclonal antibodies have been approved by regulatory 67 agencies for the use in relapsing-remitting MS (ocrelizumab, of atumumab and 68 ublituximab), and primary progressive MS (ocrelizumab). All three have been studied in 69 phase 3 randomized controlled trials (RCTs) [11–14]. These have had active comparator 70 and placebo arms and have shown to be effective in reducing the disease relapsing rates. 71 but, to our knowledge, no direct comparison between each other, or with rituximab has 72 been published. As a result, to date it is not clear whether the anti-CD20 are similar in 73 their beneficial effects and potential harms. Since head-to-head RCTs comparing the 74 interventions among them may take years if not decades, the alternative is to conduct 75 evidence synthesis methods that allow us to estimate the relative efficacy using indirect 76 evidence in the cases when direct evidence is not available.

77 Materials and Methods

78 Study registration

- 79 This protocol is reported in accordance to the Preferred Reporting Items for Meta-
- 80 Analyses Protocols (PRISMA-P) guidelines (S1 Table) [15] and has been registered in
- 81 the International Prospective Register of Systematic Reviews (PROSPERO)
- 82 (registration number CRD42023437996).

83

84 **Objective**

Assess the comparative efficacy, safety, and tolerability of anti-CD20 monoclonal
antibodies for treating relapsing MS, through a systematic review and network metaanalysis (NMA).

88

89 Eligibility criteria

90 Type of studies and participants

91 We will include phase 2b and phase 3 placebo-controlled, and active-comparator RCTs.

92 Active comparators will include any other anti-CD20 monoclonal antibody or any other

93 DMT, such as, but not restricted to: alemtuzumab, cladribine, dimethyl fumarate,

94 fingolimod, glatiramer acetate, interferon beta-1a, interferon beta-1b, pegylated

95 interferon beta-1a, natalizumab, ozanimod, siponimod, and teriflunomide. Patients 18

- 96 years of age and older with MS confirmed with 2010 or 2017 McDonald criteria
- 97 [16,17], and with a relapsing-remitting course according to the current classification

98 will be included [18]. Studies published in English or Spanish will be included, with no

- 99 restriction regarding the year of publication. Quasi-randomized, open-label, cluster and
- 100 cross-over trials will not be included.

102 Type of interventions

The interventions to be assessed are anti-CD20 monoclonal antibodies (ocrelizumab,
ofatumumab, rituximab, ublituximab) irrespective of dose, dosage form, route of
administration, administration frequency, duration of treatment, and previous exposure
to any active interventions.

107

108 **Type of outcomes**

109 Considering the prioritized outcomes suggested by the MS Core Outcome Set [19], the

primary efficacy outcome will be the annualized relapse rate (ARR) defined as the

111 number of confirmed relapses of multiple sclerosis per participant-year. The secondary

112 efficacy outcomes will be the proportion of patients with disability progression

113 confirmed at 12 week- and 24 week- (confirmed disability progression defined as an

114 increase from the baseline EDSS [Expanded Disability Status Scale] score of at least 1.0

point or 0.5 points if the baseline EDSS score was >5.5) [20], and the number of Gd+

116 lesions and the new/enlarging FLAIR/T2 lesions.

117 The primary safety outcome will be the proportion of patients with any adverse event

118 (AE) as defined by the study authors. The proportion of patients with serious adverse

events (SAE) and infusion-related reactions will be considered as secondary safety

120 outcomes.

121

122 Information sources and search strategy

123 Data sources and search strategy

124 We will search the following databases from their inception: Cochrane Central Register

125 of Controlled Trials, MEDLINE, Embase, ClinicalTrials (https://clinicaltrials.gov),

126 International Clinical Trials Registry Platform (https://www.who.int/clinical-trials-

127 registry-platform/the-ictrp-search-portal), OpenGray

128 (https://easy.dans.knaw.nl/ui/home), and MedRxiv (https://www.medrxiv.org). We will

also review the reference lists of included studies and relevant reviews for additional

- 130 studies not included after the main searches.
- 131

132 To build the search strategy a list of MeSH terms and keywords related to "anti-CD20",

133 "Antibodies, Monoclonal", "drug-modifying therapy", "multiple sclerosis", "Multiple

134 Sclerosis, Relapsing-Remitting", "ocrelizumab", "ofatumumab", "rituximab" and

135 "ublituximab" will be considered. We will use the validated RCT filter created by the

136 McMaster University Health Information Research Unit for MEDLINE and Embase

137 through the Ovid platform. These filter provide a good balance between sensitivity and

138 specificity [21].

139

140 The preliminary and the final search strategy will be based on the recommendations

141 provided by the Cochrane Handbook for Systematic Reviews of Interventions [22],

tailored to be specific for each database. A draft of the MEDLINE search strategy is

shown in Table 1. We will export all the searches results to Mendeley® version 1.19.8

144 and will remove duplicates.

145

146 Table 1. Draft of search strategy in MEDLINE (via Ovid)

Search	Terms
1	exp Multiple Sclerosis/ or Multiple Sclerosis.mp. or (exp Multiple Sclerosis,
Ĩ	Relapsing-Remitting/ or Multiple Sclerosis, Relapsing-Remitting.mp.)
2	(multiple sclerosis and (relapsing-remitting or relapsing remitting)).tw.

3	1 or 2
1	exp Antibodies, Monoclonal/ or Antibodies, Monoclonal.mp. or (exp
	Rituximab/ or Rituximab.mp.)
5	(monoclonal antibod* or antiCD20 or anti CD20 or anti-CD20 or rituximab
5	or ocrelizumab or ofatumumab or ublituximab).tw.
6	4 or 5
7	3 and 6
8	randomized controlled trial.pt.
9	randomized.mp.
10	placebo.mp.
11	8 or 9 or 10
12	7 and 11

148 Selection process, data collection and management

149 Study selection

150 Two independent reviewers (CEN, JM) will independently and in duplicate screen all he 151 retrieved titles and abstracts to determine their eligibility according to a prespecified and 152 piloted screening format. We will retrieve the full-text references of studies that at least 153 one review author considers to be eligible during the screening. The full-text records 154 will then be reviewed to determine the eligibility criteria using a prespecified and 155 piloted screening format. Disagreements between the reviewers will be resolved by 156 consensus. In the event of persistence of discrepancy between the two reviewers a third 157 evaluator will determine the eligibility (IDF). We will report a PRISMA flow diagram 158 of included and excluded articles [23]. The "Characteristics of excluded studies"

159 section will detail the primary reason for exclusions.

161 Data extraction

162 Two authors (CEN, JM) will extract data from the eligible studies using a standardized 163 data extraction form independently and in duplicate. This will include 1) characteristics 164 of the study: trial registry ID number, first author, year of publication, single or 165 multicenter study, study design, inclusion/exclusion criteria, sample size per arm, 166 recruitment and sampling procedures used, enrolment start and end dates, length of 167 participant follow-up, methods used to prevent and control for confounding, source(s) 168 of funding, authors' financial relationship and other potential conflicts of interest; 2) 169 characteristics of participants: age in years, sex, time since symptom onset, disease 170 duration, disability measured by EDSS, pre-intervention mean number of relapses, 171 mean baseline number of FLAIR/T2 and Gd+ T1 lesions, previous DMT used; 3) 172 details of the intervention and comparator: intervention, dose, formulation, frequency 173 and mode of application, duration of administration; and 4) outcome results: outcome, 174 timing of outcome measurements, number of participants randomly assigned and 175 included in the analysis, number of participants who withdrew, were lost to follow-up or 176 were excluded, number of any adverse event occurred, number of serious adverse events 177 and number of infusion-related reactions. For dichotomous outcomes we will extract the 178 number of events and number of participants randomized and for continuous outcomes, 179 the mean and standard deviations (SD) per arm.

180

181 **Risk of bias assessment**

182 Two independent reviewers (CEN, JM) will assess the risk of bias in duplicate of the

183 included studies using the Cochrane RoB 2 tool [24], which includes the following

184 domains: bias arising from the randomization process, bias due to deviations from

185 intended interventions, bias due to missing outcome data, bias in the measurement of 186 the outcome; and bias in the selection of the reported result. For each domain, we will 187 reach a risk of bias judgment, assigning one of three levels to each domain: low risk of 188 bias; some concerns; or high risk of bias. The overall risk of bias domain will be 189 classified as: 'low risk of bias' when all domains are judged as low risk, 'some 190 concerns' when at least one domain is some concern but was not high risk for any 191 domain and 'high risk' if at least one domain was high risk or if multiple domains were 192 judged as some concerns [24]. Any discrepancies will be resolved through discussion or 193 by a third reviewer (IDF). Studies will not be excluded based on the risk of bias 194 assessments, but we will conduct sensitivity analyses to explore the potential effects of 195 high risk of bias in the meta-analyses. Industry funding will be considered as a potential 196 source of bias [25].

197

198 Data synthesis

199 We will summarize trial and population characteristics, using descriptive statistics. For 200 each separate outcome, we will present a network plot of available trial data to be 201 included in the analysis. Network nodes will represent interventions compared within 202 trials and edges will represent trials directly comparing the corresponding interventions. 203 We are primarily interested in the following nodes: rituximab, ocrelizumab, 204 ofatumumab and ublituximab. We anticipate some degree of variability in the way in 205 which the interventions are administered. Namely, some interventions may have been 206 evaluated at different doses and regimens of administration. Therefore, if we identify 207 heterogeneity at the pairwise comparisons levels and this seems to be related to 208 differences in the doses or methods of administration, we will split some interventions 209 into two or more nodes to represent these differences. The size of each node will be

proportional to the number of participants in the underlying intervention, and each line
edges will be weighted according to the number of studies comparing the interventions
it connects. To identify the most influential comparisons in the network, we will present
the contribution matrix describing the contribution of each direct estimate to the entire
network of trials [26].

215

216 Statistical analysis

217 We will conduct a network meta-analysis (NMA) using a frequentist framework. We 218 will use a random-effects model to estimate the treatment effect for each drug compared 219 to placebo and with other DMT [27,28]. We will also compare the efficacy and safety of 220 each drug to each other using a network meta-analysis (NMA) using multivariate 221 distributions to allow for the simultaneous analysis of multiple interventions and 222 account for correlations induced by multi-arm trials [29]. We will calculate odds ratio 223 (OR) for dichotomous outcomes and mean differences (MD) or standardized mean 224 differences (SMD) for continuous outcomes, both with their corresponding 95% 225 confidence intervals (95%CIs). If a study does not provide enough data for conducting 226 the statistical analysis, we will try contacting the study authors. If this is not feasible, or 227 we do not obtain any response from them, and the required data is crucial for the 228 analysis (eg, mean results for continuous outcomes) we will exclude the study from the 229 pooled data and present the information narratively. In case authors provide variability 230 measures in a different format (eg, standard error, or 95%CI), we will follow the 231 recommendations by the Cochrane Handbook of Systematic Reviews to estimate the 232 required standard deviation [22]. When studies report median and ranges or interguartile 233 ranges, we will use the methods by Wan to estimate the best mean and SD [30].

234

235 Pairwise meta-analysis

237 conduct an inverse variance random-effects meta-analysis to estimate overall effect 238 using OR for dichotomous data and MD or SMD for continuous outcomes. We will 239 assess heterogeneity by visually comparing clinical and methodological characteristics 240 of the included studies and by visual inspection of study effect sizes and their variation 241 in the forest plots. We will also calculate the Chi square test for heterogeneity, and the I^2 statistic. We will consider an I^2 value >50% to be indicative of substantial heterogeneity 242 243 [31]. We will perform subgroup or sensitivity analyses to explore the potential reasons 244 behind substantial or considerable heterogeneity, namely, the potential effect modifiers.

We will conduct pairwise meta-analysis of the available direct comparisons. We will

245

236

246 A priori, we have identified the following variables might be effect modifiers: age,

relapses in the 12 months prior to randomization, disease severity according to EDSS,

248 presence of GD+ lesions in MRI, and previous use of other DMT. We hypothesize that

249 patients with younger age, high number of relapses at baseline, milder disability, the

250 presence of Gd+ lesions and no prior treatment show larger effect. To assess the

credibility of an apparent effect modification, we will use the Instrument for assessing

the Credibility of Effect Modification Analyses (ICEMAN) [32].

253

254 Network meta-analysis

We will conduct an inverse variance random-effects meta-analysis to estimate overalleffect sizes, that is respectively ORs or MDs/SMDs for dichotomous or continuous

257 outcomes, along with their corresponding 95%CIs, under the assumption that different

trials are estimating different but related true effects. We will use the Hartung-Knapp-

259 Sidik-Jonkman method to calculate a 95%CI for the overall effect size to handle meta-

analyses with a small number of studies [33]. We will rank the drugs according to theirefficacy and safety based on P-scores.

262

263 For a connected network of trials, we will conduct a random-effects NMA [34], if we 264 consider that the assumptions of transitivity and consistency are justifiable. For 265 transitivity, we are assuming that participants are equally likely to be randomized to any 266 of the included interventions and that trials are sufficiently similar across comparisons 267 with respect to their effect modifiers distribution. We will consider the same effect 268 modifiers described above as potential causes of heterogeneity. To explore variability in 269 intervention definitions, we will split them into separate nodes according to the doses 270 administered in the included trials.

271

272 The statistical manifestation of intransitivity can create inconsistency between direct 273 and indirect evidence. We will assess consistency within each network using both 274 global and local statistical approaches. We will evaluate each network using the design-275 by-treatment interaction test, and accounting for multiple sources of inconsistency due 276 to disagreements in trials with different designs [35–37]. We will also evaluate 277 consistency in each loop of interventions in each network using the loop-specific 278 approach, and between each direct and indirect evidence using the node-splitting 279 approach [38,39]. We will plot all consistency estimates and their 95%CIs to make 280 inferences about the presence of inconsistency locally in the network.

281

282 Missing data and sensitivity analysis

We will conduct sensitivity analyses to assess the robustness of our findings for theprimary outcomes. First, we will conduct an analysis by excluding studies with an

285 overall high risk of bias. If the results are very different from the analyses including all 286 studies, we will prioritize the results obtained from the studies with 'low risk' and 'some 287 concerns' analyses for our primary findings. Second, we will perform an analysis 288 excluding trials for which we imputed data. Lastly, we will perform an analysis using 289 the intention to treat denominators, in the case of trials that had data imputed. In case of 290 missing participant data, we will capture the type of data imputation used by the trial 291 authors in our extraction form, to assess the appropriateness of the data imputation 292 method. For missing outcome data, we will try to contact authors for more information. 293 If the trial authors do not respond, we will consider alternatives such as imputation 294 approaches. If the missing data from the studies are significant, we will consider this in 295 the 'Bias due to missing outcome data' criterion of the RoB 2 assessment.

296

297 We will use comparison-adjusted funnel plots to assess the likelihood of reporting bias

and small-study effects for the NMA when at least 10 studies per outcome are available

[40-42]. In the case of funnel plot asymmetry, we will explore possible sources of it,

300 including poor methodological quality in smaller trials, true heterogeneity, non-

301 reporting biases, and baseline risk differences.

302

In the cases in which the key assumptions are not met (transitivity and consistency), we
will provide only pairwise estimates and a narrative description of the results. We will
use R software version 4.3.2 (The R Foundation, Wien, Austria) for the analyses.

307 Summary of findings and assessment of the certainty of the

308 evidence

We will use the GRADE approach to assess the certainty of the direct, indirect, and network estimate for all outcomes. Two review authors (CEN, JM) will independently assess the certainty of the evidence for each outcome. Where necessary, we will resolve any disagreements between authors through discussion or by consultation with a third review author (IDF).

314

315 For the direct evidence, the assessment starts by considering evidence from RCTs to be 316 of high certainty, and the body of summarized evidence is assessed against five criteria: 317 study limitations (risk of bias) [43], inconsistency [44], indirectness [45] imprecision 318 [46], and publication bias [47]. For the "study limitations" criterion, we will use the 319 overall risk of bias assessment judgment obtained from the RoB 2 tool [24]. For the 320 specific NMA GRADE assessment we will use the specific approach that considers 321 intransitivity [48] and incoherence criteria [49] and we will apply the approach to draw 322 conclusions from the NMA sing a minimally-contextualized framework [50]. 323

324 Ethical consideration

325 This study does not require ethical approval as it is a secondary analysis of published

data. We will disseminate the results of this study through publication in a peer-

327 reviewed journal and presentation at relevant conferences.

328 Discussion and conclusion

329 This protocol outlines a network meta-analysis comparing the efficacy and safety of330 anti-CD20 monoclonal antibodies for treating relapsing multiple sclerosis.

331

332 Anti-CD20 monoclonal antibodies have shown remarkable results in terms of efficacy

333 for treating MS, which has led to their inclusion in an application to the World Health

334 Organization essential medicines list [51]. However, their relative efficacy between

them has not been assessed in controlled trials to date. Several RCTs aiming to

demonstrate the non-inferiority of rituximab in comparison to ocrelizumab are

underway [52–55], but results are expected for 2025 at the earliest. Further, to the best

of our knowledge there are no studies underway comparing the efficacy of the newer

anti-CD20 monoclonal antibodies. Therefore, the results of this study will provide

340 valuable information to guide clinical decision-making, to inform future research in this

area, and to develop new health economic evaluations related to these DMTs [56].

342

We expect difficulties for the completion of this study, for we anticipate that we willfind a limited number of RCTs, with high heterogeneity which probably will affect the

results of the meta-analysis.

346 **References**

347 1. Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple 348 sclerosis. Nat Rev Dis Prim. 2018;4: 43. doi:10.1038/s41572-018-0041-4 349 2. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising 350 prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third 351 edition. Mult Scler J. 2020;26: 1816–1821. doi:10.1177/1352458520970841 352 Frohman EM, Racke MK, Raine CS. Multiple sclerosis - The plaque and its 3. 353 pathogenesis. N Engl J Med. 2006;354: 942-955. doi:10.1056/NEJMra052130 354 4. von Büdingen H-C, Palanichamy A, Lehmann-Horn K, Michel BA, Zamvil SS. 355 Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-356 drivers and therapeutic targets. Eur Neurol. 2015;73: 238-246. 357 doi:10.1159/000377675 358 5. Xu X, Chi S, Wang Q, Li C, Xu B, Zhang J, et al. Efficacy and safety of 359 monoclonal antibody therapies for relapsing remitting multiple sclerosis: A 360 network meta-analysis. Mult Scler Relat Disord. 2018;25: 322-328. 361 doi:10.1016/j.msard.2018.08.026 362 Filippini G, Kruja J, Del Giovane C. Rituximab for people with multiple 6. 363 sclerosis. Cochrane Database Syst Rev. 2021;11: CD013874. 364 doi:10.1002/14651858.CD013874.pub2 365 7. Huygens S, Versteegh M. Modeling the cost-utility of treatment sequences for 366 multiple sclerosis. Value Heal. 2021;24: 1612–1619. 367 doi:10.1016/j.jval.2021.05.020 368 8. Chen C, Zhang E, Zhu C, Wei R, Ma L, Dong X, et al. Comparative efficacy and 369 safety of disease-modifying therapies in patients with relapsing multiple 370 sclerosis: A systematic review and network meta-analysis. J Am Pharm Assoc.

371 2023;63: 8-22.e23. doi:10.1016/j.japh.2022.07.009 372 9. Bar-Or A, Calabresi PAJ, Arnlod D, Markowitz C, Shafer S, Kasper LH, et al. 373 Rituximab in relapsing-remitting multiple sclerosis. Ann Neurol. 2008;63: 395-374 400. doi:10.1002/ana.21363 375 10. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell 376 depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 377 2008;358: 676-688. doi:10.1056/nejmoa0706383 378 Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. 11. 379 Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J 380 Med. 2017;376: 209-220. doi:10.1056/NEJMoa1606468 12. 381 Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, et al. 382 Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J 383 Med. 2017;376: 221–234. doi:10.1056/nejmoa1601277 384 Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. 13. 385 Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383: 386 546-557. doi:10.1056/nejmoa1917246 387 14. Steinman L, Fox E, Hartung H-P, Alvarez E, Qian P, Wray S, et al. Ublituximab 388 versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387: 389 704-714. doi:10.1056/NEJMoa2201904 390 15. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. 391 Preferred reporting items for systematic review and meta-analysis protocols 392 (PRISMA-P) 2015 statement. Syst Rev. 2015;4: 1-9. doi:10.1186/2046-4053-4-1 393 16. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. 394 Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald 395 criteria. Ann Neurol. 2011;69: 292-302. doi:10.1002/ana.22366

396	17.	Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al.
397		Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet
398		Neurol. 2018;17: 162–173. doi:10.1016/S1474-4422(17)30470-2
399	18.	Lublin FD, Reingold SC, Cohen JA, Cutter GR, S??rensen PS, Thompson AJ, et
400		al. Defining the clinical course of multiple sclerosis: The 2013 revisions.
401		Neurology. 2014;83: 278-286. doi:10.1212/WNL.000000000000560
402	19.	Daniels K, Frequin STFM, van de Garde EMW, Biesma DH, van der Wees PJ,
403		van der Nat PB, et al. Development of an international, multidisciplinary, patient-
404		centered Standard Outcome Set for Multiple Sclerosis: The S.O.S.MS project.
405		Mult Scler Relat Disord. 2023;69: 104461. doi:10.1016/j.msard.2022.104461
406	20.	Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded
407		disability status scale (EDSS). Neurology. 1983;33: 1444-1444.
408		doi:10.1212/WNL.33.11.1444
409	21.	Health Information Research Unit (HIRU). Search filters for MEDLINE in Ovid
410		syntax and the PubMed translation. 2023. Available:
411		https://hiruweb.mcmaster.ca/hkr/hedges/medline/
412	22.	Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane
413		Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester, UK:
414		John Wiley & Sons; 2019.
415	23.	Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al.
416		The PRISMA extension statement for reporting of systematic reviews
417		incorporating network meta-analyses of health care interventions: Checklist and
418		explanations. Ann Intern Med. 2015;162: 777-784. doi:10.7326/M14-2385
419	24.	Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB
420		2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 14898.

- 421 doi:10.1136/bmj.14898
- 422 25. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and
- 423 research outcome. Cochrane Database Syst Rev. 2012; MR000033.
- 424 doi:10.1002/14651858.MR000033.pub2
- 425 26. Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Giovane C
- 426 Del, Egger M, et al. Assessing confidence in the results of network meta-analysis
- 427 (Cinema). bioRxiv. 2019; 597047. doi:10.1101/597047
- 428 27. Rücker G. Network meta-analysis, electrical networks and graph theory. Res
- 429 Synth Methods. 2012;3: 312–324. doi:10.1002/jrsm.1058
- 430 28. Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis
- 431 works without resampling methods. BMC Med Res Methodol. 2015;15: 58.
- doi:10.1186/s12874-015-0060-8
- 433 29. Rücker G, Cates CJ, Schwarzer G. Methods for including information from
- 434 multi-arm trials in pairwise meta-analysis. Res Synth Methods. 2017;8: 392–403.

doi:10.1002/jrsm.1259

- 436 30. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard
- 437 deviation from the sample size, median, range and/or interquartile range. BMC

438 Med Res Methodol. 2014;14: 135. doi:10.1186/1471-2288-14-135

- 439 31. Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327: 557–
 440 560. doi:10.1136/bmj.327.7414.557
- 441 32. Schandelmaier S, Briel M, Varadhan R, Schmid CH, Devasenapathy N, Hayward
- 442 RA, et al. Development of the Instrument to assess the Credibility of Effect
- 443 Modification Analyses (ICEMAN) in randomized controlled trials and meta-
- 444 analyses. Can Med Assoc J. 2020;192: E901–E906. doi:10.1503/cmaj.200077
- 445 33. Veroniki AA, Jackson D, Bender R, Kuss O, Langan D, Higgins JPT, et al.

446		Methods to calculate uncertainty in the estimated overall effect size from a
447		random-effects meta-analysis. Res Synth Methods. 2019;10: 23-43.
448		doi:10.1002/jrsm.1319
449	34.	Salanti G. Indirect and mixed-treatment comparison, network, or multiple-
450		treatments meta-analysis: many names, many benefits, many concerns for the
451		next generation evidence synthesis tool. Res Synth Methods. 2012;3: 80-97.
452		doi:10.1002/jrsm.1037
453	35.	Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and
454		inconsistency in network meta-analysis: concepts and models for multi-arm
455		studies. Res Synth Methods. 2012;3: 98-110. doi:10.1002/jrsm.1044
456	36.	White IR, Barrett JK, Jackson D, Higgins JPT. Consistency and inconsistency in
457		network meta-analysis: model estimation using multivariate meta-regression. Res
458		Synth Methods. 2012;3: 111–125. doi:10.1002/jrsm.1045
459	37.	Krahn U, Binder H, König J. A graphical tool for locating inconsistency in
460		network meta-analyses. BMC Med Res Methodol. 2013;13: 35.
461		doi:10.1186/1471-2288-13-35
462	38.	Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed
463		treatment comparison meta-analysis. Stat Med. 2010;29: 932-944.
464		doi:10.1002/sim.3767
465	39.	Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency
466		in networks of interventions. Int J Epidemiol. 2013;42: 332–345.
467		doi:10.1093/ije/dys222
468	40.	Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a
469		simple, graphical test. BMJ. 1997;315: 629-634. doi:10.1136/bmj.315.7109.629
470	41.	Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of

471 small-study effects in a network of interventions. Res Synth Methods. 2012;3:

472 161–176. doi:10.1002/jrsm.57

- 473 42. Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G. Graphical tools
 474 for network meta-analysis in STATA. PLoS One. 2013;8: e76654.
- 475 doi:10.1371/journal.pone.0076654
- 476 43. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al.
- 477 GRADE guidelines: 4. Rating the quality of evidence study limitations (risk of
- 478 bias). J Clin Epidemiol. 2011;64: 407–415. doi:10.1016/j.jclinepi.2010.07.017
- 479 44. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al.
- 480 GRADE guidelines: 7. Rating the quality of evidence inconsistency. J Clin
 481 Epidemiol. 2011;64: 1294–1302. doi:10.1016/j.jclinepi.2011.03.017
- 482 45. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al.
- 483 GRADE guidelines: 8. Rating the quality of evidence indirectness. J Clin

484 Epidemiol. 2011;64: 1303–1310. doi:10.1016/j.jclinepi.2011.04.014

- 485 46. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al.
- 486 GRADE guidelines 6. Rating the quality of evidence imprecision. J Clin
- 487 Epidemiol. 2011;64: 1283–1293. doi:10.1016/j.jclinepi.2011.01.012
- 488 47. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE
- 489 guidelines: 5. Rating the quality of evidence publication bias. J Clin Epidemiol.
- **490** 2011;64: 1277–1282. doi:10.1016/j.jclinepi.2011.01.011
- 491 48. Brignardello-Petersen R, Tomlinson G, Florez I, Rind DM, Chu D, Morgan R, et
- 492 al. Grading of recommendations assessment, development, and evaluation
- 493 concept article 5: addressing intransitivity in a network meta-analysis. J Clin
- 494 Epidemiol. 2023;160: 151–159. doi:10.1016/j.jclinepi.2023.06.010
- 495 49. Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk RA, Furukawa

- 496 TA, Rochwerg B, et al. Advances in the GRADE approach to rate the certainty in
- 497 estimates from a network meta-analysis. J Clin Epidemiol. 2018;93: 36–44.

doi:10.1016/j.jclinepi.2017.10.005

- 499 50. Brignardello-Petersen R, Florez ID, Izcovich A, Santesso N, Hazlewood G,
- 500 Alhazanni W, et al. GRADE approach to drawing conclusions from a network
- 501 meta-analysis using a minimally contextualised framework. BMJ. 2020; m3900.

502 doi:10.1136/bmj.m3900

- 503 51. The Lancet Neurology. Towards equitable access to treatment for multiple
- 504 sclerosis. Lancet Neurol. 2023;22: 189. doi:10.1016/S1474-4422(23)00041-8
- 505 52. Torkildsen Ø, Myhr K-M. Ocrelizumab versus rituximab off-label at the onset of

506 relapsing MS disease (OVERLORD-MS). 2020. Available:

- 507 https://clinicaltrials.gov/study/NCT04578639
- 508 53. Christensen JR, Sellebjerg F. Non-inferiority study of ocrelizumab and rituximab
- 509 in active multiple sclerosis (DanNORMS). 2020. Available:
- 510 https://clinicaltrials.gov/study/NCT04688788
- 511 54. Michel L, Gazzola A. RItuximab versus ocrelizumab in relapsing-remitting
- 512 multiple sclerosis (TRIO). 2023. Available:
- 513 https://clinicaltrials.gov/study/NCT05758831
- 514 55. Schoof L, Strijbis E. Non-inferiority study of rituximab compared to ocrelizumab
- 515 in relapsing MS (Noisy Rebels). 2023. Available:
- 516 https://clinicaltrials.gov/study/NCT05834855
- 517 56. Navarro CE, Betancur JE. Cost-utility analysis comparing ocrelizumab vs
- 518 rituximab in the treatment of relapsing-remitting multiple sclerosis: The
- 519 Colombian perspective. Value Heal Reg Issues. 2023;36: 83–91.
- 520 doi:10.1016/j.vhri.2023.02.008

521 Supporting information

- 522 S1 Table. PRISMA-P (Preferred Reporting Items for Systematic review and Meta-
- 523 Analysis Protocols) 2015 checklist